Immuno-Oncology | Specialty

Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC

November 9th 2023

Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial.

Domvanalimab Plus Zimberelimab and Chemotherapy Elicits Responses in Advanced Gastric/GEJ Adenocarcinoma

November 7th 2023

The combination of domvanalimab, zimberelimab, and FOLFOX elicited responses in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, irrespective of PD-L1 status.

Atezolizumab Plus Bevacizumab and Chemo Improves Survival in Metastatic or Recurrent Cervical Cancer

November 3rd 2023

The addition of atezolizumab to bevacizumab and chemotherapy resulted in a significant improvement in progression-free survival and overall survival vs standard treatment with bevacizumab and chemotherapy in patients with metastatic, persistent, or recurrent cervical cancer.

Adjuvant Pembrolizumab Improves OS in Select Patients With RCC After Nephrectomy

November 1st 2023

Adjuvant treatment with pembrolizumab significantly improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions, meeting a key secondary end point of the phase 3 KEYNOTE-564 trial.

EMA Validates Application for Frontline Nivolumab Plus Chemo in Advanced Urothelial Cancer

October 30th 2023

The European Medicines Agency has validated a type II variation application for the first-line combination of nivolumab and cisplatin-based chemotherapy for adult patients with unresectable or metastatic urothelial carcinoma.

Expanding Immunotherapy Armamentarium Propels Personalized HCC Treatment Approaches

October 28th 2023

Richard Kim, MD, discusses the range of systemic treatment options available for patients with unresectable hepatocellular carcinoma and the importance of assessing patients for high-risk disease criteria before beginning any systemic treatment.

ImPrint Biomarker Predicts Immunotherapy Response in Patients With HR+/HER2– Breast Cancer

October 25th 2023

Denise M. Wolf, PhD, discusses the methods used to conduct the I-SPY2 study and the implications that immune biomarkers could have on selecting treatment for patients with hormone receptor–positive, HER2-negative breast cancer in the future.

Updated Data Continue to Aid IO-Based Frontline Treatment Decisions in Advanced RCC

October 24th 2023

Tian Zhang, MD, MHS, details how updated data presented at the 2023 ASCO Annual Meeting from trials such as KEYNOTE-426 and CLEAR have showed the sustained efficacy of VEGF plus immunotherapy combinations vs sunitinib in the first-line setting; discusses where the immunotherapy-only combination of ipilimumab and nivolumab fits in the frontline setting; and highlights how data from CONTACT-03 provided key insights on the use of immunotherapy in patients with advanced renal cell carcinoma after progression on a prior immune checkpoint inhibitor.

Retrospective Data Show Nephrectomy With Immune-Targeted Therapy Offers Potential PFS Benefit in Metastatic RCC

October 24th 2023

Nephrectomy with immune-targeted therapy was associated with a progression-free survival benefit compared with immunotherapy alone in patients with metastatic renal cell carcinoma.

Frontline Enfortumab Vedotin Plus Pembrolizumab Elicits OS Improvement in Advanced Urothelial Carcinoma

October 22nd 2023

Frontline treatment with the combination of enfortumab vedotin-ejfv and pembrolizumab led to a statistically significant improvement in overall survival vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer

October 21st 2023

The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.

Perioperative Nivolumab Significantly Improves EFS in Previously Untreated Resectable NSCLC

October 21st 2023

Neoadjuvant treatment with nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab resulted in a statistically significant improvement in event-free survival vs placebo plus chemotherapy, in patients with previously untreated resectable stage II to IIIB non-small cell lung cancer, according to data from the phase 3 CheckMate 77T trial.

Lifileucel Demonstrates Efficacy in Advanced Mucosal Melanoma Following Progression on Immune Checkpoint Inhibitors

October 21st 2023

Lifileucel demonstrated clinically meaningful activity in patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors, according to findings from a subgroup of patients in the phase 2 C-144-01 study.

Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2– Breast Cancer

October 20th 2023

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Subcutaneous Nivolumab Meets PK and ORR End Points in Pretreated Advanced or Metastatic ccRCC

October 19th 2023

Treatment with subcutaneous nivolumab co-formulated with recombinant human hyaluronidase demonstrated noninferior pharmacokinetics vs intravenous nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma who received prior systemic therapy.

FDA Approves Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

October 14th 2023

The FDA has approved nivolumab (Opdivo) for the adjuvant treatment of adult and pediatric patients 12 years of age and older with completely resected stage IIB or IIC melanoma.

CHMP Recommends First-Line Pembrolizumab Plus Chemotherapy for PD-L1+, HER2– Advanced Gastric/GEJ Adenocarcinoma

October 13th 2023

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

TJ-L14B/ABL503 Showcases Early Efficacy Signals in Advanced or Metastatic Solid Tumors

October 10th 2023

TJ-L14B/ABL503 demonstrated preliminary efficacy signals in the form of responses in patients with progressive, locally advanced or metastatic solid tumors who were relapsed or refractory after previous lines of therapy.

Perioperative Pembrolizumab Meets Dual Primary End Point of OS in NSCLC

October 10th 2023

Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.

Dr Aerts on the Rationale for the DENIM Trial in Mesothelioma

October 5th 2023

Joachim G. J. V. Aerts, MD, PhD, discusses the rationale for conducting the phase 3 DENIM trial in patients with mesothelioma, highlighting the importance of focusing investigational efforts onto the dendritic cells.